Disclaimer<\/b><\/p> \n
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.<\/p> \n
關于諾華<\/b><\/p> \n
諾華正在通過創想醫藥未來以改善人們生活質量、延長人類壽命。作為全球知名的醫藥健康企業，我們運用創新科學和數字化技術，在醫藥健康需求增長的領域創造變革性的治療方法。在探索新藥物的過程中，我們不懈創新，對研發的投資一直處于行業全球先列。在全球，超過7.99億患者受益于諾華產品，同時，我們持續探索更多創新方式使我們的創新療法造福更多患者。諾華在全球擁有來自超過140個國家的約10.9萬名員工。如需更多信息，敬請登錄公司網站：www.novartis.com<\/a> 。<\/p> \n 關于諾華中國<\/b><\/p> \n “諾華”中文取意“承諾中華”，即承諾通過不斷創新的產品和服務，致力于提高中國人民的健康水平和生活質量。諾華在中國的業務包括諾華腫瘤、諾華制藥和山德士，全國建有兩大生產基地，并在北京、上海和江蘇設立了研發機構。從研發到生產銷售，諾華以多元化的業務組合，全面服務中國老百姓的健康。目前，諾華在中國擁有8000多名員工。如需更多信息，敬請登錄公司中文網站http:\/\/www.novartis.com.cn<\/a>。<\/p> \n 圖片 - https:\/\/photos.prnasia.com\/prnh\/20200616\/2832061-1-a?lang=1<\/a>
圖片 - https:\/\/photos.prnasia.com\/prnh\/20200616\/2832061-1-b?lang=1<\/a>
圖片 - https:\/\/photos.prnasia.com\/prnh\/20200616\/2832061-1-c?lang=1<\/a>
圖片 - https:\/\/photos.prnasia.com\/prnh\/20200616\/2832061-1-d?lang=1<\/a><\/p>"];
$("#dvExtra").html(content_array[0]);})();